Tandem Diabetes Care Inc (NASDAQ:TNDM) Shorted Shares Decreased By 0.37%

June 27, 2018 - By Maria Fierro

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Corporate Logo

It was recorded a decrease on Tandem Diabetes Care Inc (NASDAQ:TNDM)’s shares shorted with 0.37%. In June was issued TNDM’s total 2.01 million shares shorted by FINRA. The 2.01M previous shares are down with 0.37%. With Average volume 1.59M, TNDM’s former position will take 1 days to restore.

TNDM is touching $23.64 during the last trading session, after increased 0.42%.Tandem Diabetes Care, Inc. is uptrending after having risen 73.21% since June 27, 2017. TNDM has 4.18M volume or 56.30% up from normal. TNDM outperformed the S&P500 by 60.64%.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.The firm is worth $1.18 billion. The company??s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set.Last it reported negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Ratings Coverage

Total analysts of 6 have positions in Tandem Diabetes Care (NASDAQ:TNDM) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. The firm has $30 highest while $4.0 is the lowest price target. The average target $11.63 is -50.80% below the last ($23.64) price. Since February 27, 2018 according to StockzIntelligence Inc Tandem Diabetes Care has 7 analyst reports. The company rating was upgraded by PiperJaffray on Monday, May 14. On Tuesday, February 27 the stock has “Hold” rating by Cowen & Co. On Friday, March 2 the rating was maintained by Stifel Nicolaus with “Hold”. On Wednesday, March 28 Cowen & Co upgraded Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to “Buy” rating. In Friday, March 23 report Robert W. Baird upgraded the stock to “Outperform” rating.

For more Tandem Diabetes Care, Inc. (NASDAQ:TNDM) news published recently go to: Seekingalpha.com, Seekingalpha.com, Fool.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Premarket analyst action – healthcare” published on June 18, 2018, “Epic Rally In Tandem Diabetes Care, Can It Continue?” on June 25, 2018, “Tandem Diabetes Takes Aim at Medtronic’s Artificial Pancreas” with a publish date: June 24, 2018, “Pre-Open Movers 06/22: (WSC) (TNDM) (KMX) Higher; (GRBK) (RHT) (YTRA) Lower (more…)” and the last “Mid-Day Market Update: Crude Oil Up Over 4%; WillScot Shares Spike Higher” with publication date: June 22, 2018.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.